


Encequidar mesylate hydrochloride

Cat. No.:	HY-13646C
CAS No.:	2097125-58-9
Molecular Formula:	C ₃₉ H ₄₂ N ₆ O ₁₁ S
Molecular Weight:	802.85
Target:	P-glycoprotein
Pathway:	Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Encequidar (HM30181) mesylate hydrochloride is a potent and selective inhibitor of P-glycoprotein (MDR1). Encequidar mesylate hydrochloride improves anti-tumor efficacy of Paclitaxel (HY-B0015) in mouse tumor models^{[1][2][3]}.

CUSTOMER VALIDATION

- Nat Commun. 2021 Jan 12;12(1):312.
- Crit Rev Anal Chem. 2021 Mar 10;1-15.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Bauer F, et al. Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography. *Eur J Pharmacol.* 2012 Dec 5;696(1-3):18-27.
- [2]. Kim TE, et al. Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers. *Br J Clin Pharmacol.* 2014 Sep;78(3):556-64.
- [3]. McCaw ZR, et al. Assessing the Clinical Utility of Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer. *J Clin Oncol.* 2023 Feb 20;41(6):1323.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA